从正常供者动员干细胞：能否改进 G-CSF？
Mobilizing stem cells from normal donors: is it possible to improve upon G-CSF?
目前粒细胞集落刺激因子（G-CSF）仍是外周血干细胞捐献者标准动员剂，但存在明显副作用且需多日给药。另一种获批的粒细胞-巨噬细胞集落刺激因子（GM-CSF）可改变移植物组成，但部分供者动员不足或毒性难以接受。AMD3100 是一种有前景的新动员剂，它直接阻断趋化因子 SDF-1 与其受体 CXCR4 的相互作用，能在数小时内而非数天内动员干细胞，且迄今临床试验中耐受良好，未报告明显副作用。使用 AMD3100 动员的移植物在自体及异体移植中均显示快速、稳定的植入。本文综述了正常供者干细胞动员的现状，并讨论了新的动员策略。
为什么推荐给您：综述性文章，讨论已有动员剂优劣，无新数据或新方法，属常规进展。
不需要生物学背景，多打比方
正在获取全文并生成讲解（拿不到全文就依据摘要），大约需要 30–60 秒…
已等待 0 秒
这篇还没有动画
动画会把研究的流程、作用机制和关键结果一步一步演示出来，每一步都标明出自原文哪里。制作大约需要 30–60 秒。
摘要Abstract
Currently, granulocyte colony stimulating factor (G-CSF) remains the standard mobilizing agent for peripheral blood stem cell (PBSC) donors, allowing the safe collection of adequate PBSCs from the vast majority of donors. However, G-CSF mobilization can be associated with some significant side effects and requires a multi-day dosing regimen. The other cytokine approved for stem cell mobilization, granulocyte-macrophage colony stimulating factor (GM-CSF), alters graft composition and may reduce the development of graft-versus-host disease, but a significant minority of donors fails to provide sufficient CD34+ cells with GM-CSF and some experience unacceptable toxicity. AMD3100 is a promising new mobilizing agent, which may have several advantages over G-CSF for donor mobilization. As it is a direct antagonist of the interaction between the chemokine stromal-derived factor-1 and its receptor CXCR4, AMD3100 mobilizes PBSCs within hours rather than days. It is also well tolerated, with no significant side effects reported in any of the clinical trials to date. Studies of autologous and allogeneic transplantation of AMD3100 mobilized grafts have demonstrated prompt and stable engraftment. Here, we review the current state of stem cell mobilization in normal donors and discuss novel strategies for donor stem cell mobilization.